NorthWest Biotherapeutics Inc (NWBO)

[Maverick0408]

BS. FDA or MHRA will not hold up an effective therapy for GBM because of the potential tumor agnostic implications. They know it’s not practical to put massive manufacturing burden on small companies at the onset of their commercial journey. Must take baby steps. They would rather approve it for GBM which is more on an unmet need than ask them to hold off on applying until manufacturing has scaled up to a point where they can meet demand for other cancers too. Does not make any sense! They know this scenario is unlikely to play out and they will choke the company to death. That’s not what the regulators are for.